


Data Sheet

Product Name:	MK-0429
Cat. No.:	CS-0003761
CAS No.:	227963-15-7
Molecular Formula:	C ₂₃ H ₂₉ N ₅ O ₄
Molecular Weight:	439.51
Target:	Integrin
Pathway:	Cytoskeleton
Solubility:	DMSO : 250 mg/mL (568.82 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide **αvβ3 integrin** antagonist with an **IC₅₀** of 80 nM. IC₅₀ & Target: IC₅₀: 80 nM (αvβ3 integrin)^[1] **In Vivo**: MK-0429 (100 or 300 mg/kg, p.o., twice daily b.i.d., 2 weeks) reduces metastatic tumor colony formation and area in the lungs. MK-0429 is safe and efficacious in significantly decreasing melanoma metastasis in the lungs [1].

References:

[1]. Hutchinson JH, et al. Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. J Med Chem. 2003 Oct 23;46(22):4790-8.

[2]. Pickarski M, et al. Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep. 2015 Jun;33(6):2737-45.

CAIndexNames:

3-Pyridinepropanoic acid, 6-methoxy- -[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]-, (S)-

SMILES:

O=C1N([C@H](C2=CC=C(OC)N=C2)CC(O)=O)CCN1CCCC3=NC4=C(C=C3)CCCN4

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA